We previously demonstrated that the intravenous anesthetic, propofol, restores the sensitivity of transient receptor potential vanilloid channel subtype-1 (TRPV1) receptors via a protein kinase C epsilon (PKCe)-dependent and transient receptor potential ankyrin channel subtype-1 (TRPA1)-dependent pathway in sensory neurons. The extent to which the two pathways are directly linked or operating in parallel has not been determined. Using a molecular approach, our objectives of the current study were to confirm that TRPA1 activation directly results in PKCe activation and to elucidate the cellular mechanism by which this occurs. F-11 cells were transfected with complimentary DNA (cDNA) for TRPV1 only or both TRPV1 and TRPA1. Intracellular Ca 2+ concentration was measured in individual cells via fluorescence microscopy. An immunoblot analysis of the total and phosphorylated forms of PKCe, nitric oxide synthase (nNOS), and TRPV1 was also performed. In F-11 cells containing both channels, PKCe inhibition prevented the propofol-and allyl isothiocyanate (AITC)-induced restoration of TRPV1 sensitivity to agonist stimulation as well as increased phosphorylation of PKCe and TRPV1. In cells containing TRPV1 only, neither agonist induced PKCe or TRPV1 phosphorylation. Moreover, NOS inhibition blocked propofol-and AITC-induced restoration of TRPV1 sensitivity and PKCe phosphorylation, and PKCe inhibition prevented the nitric oxide donor, SNAP, from restoring TRPV1 sensitivity. Also, propofol-and AITC-induced phosphorylation of nNOS and nitric oxide (NO) production were blocked with the TRPA1-antagonist, HC-030031. These data indicate that the AITC-and propofol-induced restoration of TRPV1 sensitivity is mediated by a TRPA1-dependent, nitric oxide synthase-dependent activation of PKCe.
Introduction
Two prominent members of the transient receptor potential (TRP) family, the vanilloid subtype-1 (TRPV1) receptor and the ankyrin subtype-1 (TRPA1) receptor are extensively coexpressed in peripheral sensory neurons and function as sensory transducers of noxious stimuli (Caterina et al. 2001; Palazzo et al. 2008) . The relative sensitivity of these receptors to their respective agonists can have a major impact on nociceptive signaling in health and disease. Several chemical agents are capable of acutely sensitizing TRPV1 receptors to thermal mediators resulting in the sensation of pain (Lu et al. 2006; Novakova-Tousova et al. 2007; Holzer 2008; Wang 2008) , whereas desensitization of the receptor via repetitive stimulation plays an important role in blocking pain transmission (Mandadi et al. 2004; Larrucea et al. 2008) . Recent evidence has suggested that cross talk between TRPV1 and TRPA1 receptors may serve to integrate distinct nociceptive signaling pathways and provide a novel mechanism for integration of nociceptive information (Akopian et al. 2007 Ruparel et al. 2008; Salas et al. 2009 ). Little is known about the cellular signaling pathways by which TRPV1 and TRPA1 channels communicate with each other in sensory neurons.
Propofol is one of the most commonly used intravenous anesthetics for the induction and maintenance of general anesthesia and sedation. Apart from its anesthetic properties, propofol has several nonanesthetic effects, one of which is the activation of TRPA1 ion channels to enhance pain and inflammation (Matta et al. 2007 ). Our laboratory has recently shown that propofol restores the sensitivity of TRPV1 receptors following agonist-induced desensitization via a TRPA1 dependent pathway in mouse dorsal root ganglion (DRG) sensory neurons . Moreover, we also demonstrated in an earlier study that the propofol-induced restoration of TRPV1 sensitivity occurs via a protein kinase C epsilon (PKCe)-dependent phosphorylation of the TRPV1 receptor (Wickley et al. 2010) . The extent to which the actions of propofol on TRPA1 and PKCe signaling pathways operate independently in parallel or are directly linked has not been determined. Moreover, the mechanism by which TRPA1 activation stimulates PKCe autophosphorylation and activation is also not known. We rationalized that activation of nitric oxide synthase (NOS) and production of nitric oxide (NO) following TRPA1 stimulation may play a role in mediating PKCe activation, at least in part, since TRPA1 activation has been associated with NO production in human lung carcinoma cells (Sun et al., 2014) and NO selectively activates PKCe in isolated adult rabbit hearts (Ping et al. 1999) . Therefore, our objectives were to confirm that TRPA1 activation directly results in PKCe activation and to elucidate the cellular mechanism by which this occurs.
In the current study, we tested the hypothesis that inhibition of PKCe attenuates the restoration of TRPV1 sensitivity induced by the TRPA1 agonists, allyl isothiocyanate (AITC) and the general anesthetic, propofol. Moreover, we also tested the hypothesis that the presence of TRPA1 receptors is required for the propofol-and AITC-induced activation of PKCe as well as subsequent phosphorylation of TRPV1 receptors. Finally, we tested the hypothesis that TRPA1-dependent activation of NOS and NO production are involved in the autophosphorylation/activation of PKCe and restoration of TRPV1 sensitivity to agonist stimulation.
Materials and Methods
F-11 cell transfection with TRPV1 or TRPA1 cDNA Cultured F-11 cells (DRG-like hybridoma cell line) were transfected with TRPV1 or TRPA1 cDNA via electroporation using the Neon Transfection System (Invitrogen, Carlsbad, CA) as per the manufacturer's instructions for F-11 cells. Briefly, cultured F-11 cells at 80% confluence were harvested and washed with phosphate-buffered saline (PBS) without Ca 2+ or Mg 2+ . The cells were resuspended in 100 lL of electrolytic Buffer R in a sterile eppendorf tube and 5 lg of either TRPV1 or TRPA1 cDNA was then added. Electroporation was performed using a pulse voltage of 1500 V, a pulse width of 35 msec and a pulse number of 2. Following electroporation, the cells were then suspended in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum at 37°C. A proportion of the cells were seeded onto coverslips in 6-well dishes and used for intracellular Ca 2+ measurements, while the remainder were used for immunoblot analysis to confirm the presence and/ or absence of TRPV1 and TRPA1.
Intracellular Ca
2+ measurements F-11 cells were incubated at room temperature (23°C) for 15 min with fura-2 acetoxy methylester (fura-2/AM; 2 lmol/L) in HEPES-buffered (2-[4-(2-hydroxyethyl) piperazin-1-yl]ethanesulfonic acid saline containing the following: 118 mmol/L NaCl, 4.8 mmol/L KCl, 1.2 mmol/L MgCl 2 , 1.25 mmol/L CaCl 2 , 11.0 mmol/L dextrose, 5 mmol/L pyruvate, and 25 mmol/L HEPES (pH 7.35). Coverslips containing the fura-2-loaded F-11 cells were placed in a temperature-regulated (30°C) chamber (Warner Instruments, Hamden, CT) mounted on the stage of an Olympus IX-81 inverted fluorescence microscope (Olympus America, Lake Success, NY). The cells were superfused continuously with HEPES-buffered saline at a flow rate of 2 mL/ min. Drugs were delivered by switching from control buffer to drug-containing buffer for 20 sec unless noted otherwise. Intracellular free Ca 2+ concentration ([Ca 2+ ] i ) measurements were simultaneously performed on multiple individual cells using a fluorescence imaging system (Easy Ratio Pro, Photon Technology International, Lawrenceville, NJ) equipped with a multiwavelength spectrofluorometer (DeltaRAM X) and a QuantEM 512SC electron multiplying charge-coupled device camera (Photometrics, Tuscon, AZ). Images and photometric data were acquired by alternating excitation wavelengths between 340 and 380 nm (20 Hz) and monitoring an emission wavelength of 510 nm. Due to the fact that calibration procedures rely on a number of assumptions, the ratio of the light intensities at the two wavelengths was used to measure qualitative changes in [Ca 2+ ] i . Just before data acquisition, background fluorescence was measured and automatically subtracted from the subsequent experimental measurement using Easy Ratio Pro.
Immunoblot analysis of PKCe, TRPV1, and nNOS (total and phosphorylated)
Immunoblot analysis was carried out on whole F-11 cell lysates . Protein concentration was assessed using the Bradford method (Bradford 1976 (Cell Signaling, 32 Tozer Road, Beverly MA, 01915, USA) were diluted 1:1000 in Tris-buffered saline containing 1% bovine serum albumin for immunoblotting (2 h). After washing in Tris-buffered saline three times (10 min each), membranes were incubated for 1 h at room temperature with horseradish-peroxidaselinked secondary antibody (goat anti-mouse and goat anti-rabbit; 1:5000 dilution in Tris-buffered saline containing 1% bovine serum albumin). Membranes were again washed and bound antibody was detected by enhanced chemiluminescence. Immunoreactivity was quantified by scanning densitometry and analyzed using software (ImageJ; National Institutes of Health, Washington, DC).
Selection criteria for determining subpopulations of transfected F-11 neurons F-11 cells (Platika et al. 1985 ) that either transfected with only TRPV1 receptors or both TRPV1 and TRPA1 receptors were first identified by treating the cells with single applications of capsaicin and AITC. Cells responsive to only capsaicin were deemed to contain only functional TRPV1 receptors, while cells that were responsive to capsaicin and AITC were deemed to contain both TRPV1 and TRPA1 receptors. Cells that did not respond to capsaicin or AITC were excluded from the study and therefore were not used in the statistical analysis.
Measurement of NO production in TRPV1-TRPA1 cotransfected F-11 cells and fluorescence microscopy NO detection kit for fluorescence microscopy was purchased from ENZO Life Sciences (10 Executive Boulevard, Farmingdale, NY, 11735, USA). All reagents were diluted in accordance to the product instructions. Cells were seeded the day before the experiment to ensure 50-70% confluency on the day of the experiment and were cultured in L-Arginine free media. On the day of the experiment, cells were pretreated with the NO scavenger c-PTIO and incubated with the NO detection reagent for 2 h. Cells were washed twice with wash buffer and then treated with experimental test agents including propofol (10 lmol/L), AITC (100 lmol/L), SNAP (100 lmol/L), and HC-030031 (0.5 lmol/L). Cells were treated with the NOinducer, L-Arginine (100 lmol/L) and the NO-scavenger, 2-4-carboxyphenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (c-PTIO;10 lmol/L) as positive and negative controls, respectively. Posttreatment, cells were rinsed with wash buffer and examined under a fluorescence/confocal microscope (Olympus IX-70, FV5 PSU, Olympus America, 3500 Corporate Parkway, Center Valley, PA, 18034, USA) using the filter set Cyanine 5 (650/670 nm).
Composition of propofol
The Diprivan â lipid emulsion form of propofol (56 mmol/ L [10 mg/mL] propofol, 10% soybean oil, 2.25% glycerol, 1.2% purified phospholipid) was used in all protocols and will be referred to as propofol throughout the manuscript. Intralipid vehicle was used as a control. The effect of Intralipid was examined at concentrations equivalent to those used for the propofol-Intralipid mixture.
Statistical analysis
All Ca 2+ imaging experimental protocols were repeated in a minimum of five separate coverslips of F-11 cells. Results obtained from each coverslip (for F-11 cell experiments) were averaged so that all coverslips of cells were weighted equally. Gaussian distribution was examined by the Shapiro-Wilk normality test. Comparisons between the groups were made using repeated-measures one-way analysis of variance and the Bonferroni post hoc test. Differences were considered statistically significant at P < 0.05. All results are expressed as mean AE SEM. The error bars in the figures refer to the variability in the peak of the Ca 2+ response (Ca 2+ imaging) or to the variability in intensity of the bands (immunoblot analysis) compared to the untreated control or a specific intervention, as noted in the legends. Statistical analysis was conducted using Sigma Plot 12.5 software (Systat Software, San Jose, CA).
Results
Effect of PKCe inhibition on AITC-and propofol-induced restoration of TRPV1 sensitivity to agonist stimulation in cultured TRPA1-TRPV1 co-transfectedF-11 cells Individual F-11 cells containing both functional TRPV1 and TRPA1 receptors were first identified by treating the cells with single applications of capsaicin (100 nmol/L) and AITC (100 lmol/L) a (Fig. 1A) . Repetitive stimulation of F-11 cells with capsaicin resulted in a progressive decrease
Representative trace depicting the effect of a single application of the specific transient receptor potential vanilloid subtype-1 (TRPV1) agonist capsaicin (Cap; 100 nmol/L) and the specific transient receptor potential ankyrin receptor subtype-1 (TRPA1) activator allyl isothiocyanate (AITC, 100 lmol/L) on intracellular free calcium concentration in F11 cells transfected with both TRPA1 and TRPV1 complementary DNA (cDNA). Representative traces depicting the effect of AITC (100 lmol/L) alone, propofol (Prop, 10 lmol/L) alone, AITC in the presence of specific PKCe inhibitor eV1-2 (0.5 lmol/L), propofol in the presence of specific PKCe inhibitor eV1-2 after capsaicin-induced (100 nmol/L) desensitization on restoration of TRPV1 sensitivity in F-11 cells transfected with both TRPA1 and TRPV1 cDNA are depicted in Figure 1B , C, D, and E, respectively. The eV1-2 inhibitor peptide was added alone for 5 min following desensitization and then AITC or propofol was brought on board in combination with the eV1-2 inhibitor peptide for an additional 5 min. Summarized data for Figure 1B -E are depicted in Figure 1F . Data are expressed as a percent of the response to the final application of capsaicin in the untreated control (% of control mean value AE SEM). *P < 0.05 compared to final capsaicin in the untreated control. #P < 0.05 compared to AITC plus capsaicin. †P < 0.05 compared to propofol plus capsaicin. n = seven separate coverslips of F-11 cells were used. (de-sensitization) in peak [Ca 2+ ] i (Fig. 1B) . When AITC (100 lmol/L) was added to the bath during the 10 min pause in stimulation, subsequent reapplication of capsaicin resulted in a robust transient increase in [Ca 2+ ] i (resensitization) (Fig. 1B) . A similar resensitizing effect was observed with propofol (Fig. 1C) . Pretreatment with the PKCe-specific inhibitory peptide eV1-2 (0.5 lmol/L) following desensitization inhibited the AITC-and propofol-induced restoration of TRPV1 sensitivity to capsaicin compared with F-11 cells treated only with propofol or AITC ( Fig. 1D and E) . Summarized data depicting the effect of AITC and propofol alone or in the presence of eV1-2 on restoration of TRPV1 sensitivity to capsaicin in TRPV1-TRPA1 cotransfected F-11 cells are depicted in Figure 1F . Summarized results are expressed as a percent of the response to the final application of capsaicin in untreated cells (control).
Effect of PKCe activation on restoration of TRPV1 sensitivity to agonist stimulation in TRPV1 transfected F-11 cells F-11 cells containing only TRPV1 receptors were first identified by treating the cells with single applications of capsaicin (100 nmol/L) and AITC (100 lmol/L). Cells that responded with a transient increase in [Ca 2+ ] i subsequent only to capsaicin were selected for the experiment (Fig. 2A) . Repetitive stimulation of F-11 cells with capsaicin resulted in a progressive decrease (desensitization) in peak [Ca 2+ ] i that was maintained following a 10-min pause in capsaicin stimulation as indicated by the lack of any response to capsaicin after reapplication of capsaicin to the bath (Fig. 2B) . In contrast, when the PKCe activator peptide weRACK (0.5 lmol/L) was added to the bath during the 10-min pause in stimulation, subsequent reapplication of capsaicin resulted in a robust transient increase in [Ca 2+ ] i (resensitization) (Fig. 2C) . Summarized data depicting the effect of weRACK (0.5 lmol/L) on TRPV1 resensitization are depicted in Figure 2D . Summarized results are expressed as a percent of the response to the final application of capsaicin during the initial desensitization of TRPV1.
Effect of AITC and propofol on phosphorylation of PKCe at S729 in cultured F11 cells expressing TRPV1 only or both TRPV1 and TRPA1
To determine if the presence of TRPA1 receptors is required for propofol or AITC to activate PKCe at S729, immunoblot analysis of PKCepS 729 was performed before and after treatment of cells with either propofol (10 lmol/ L; 10 min), AITC (100 lmol/L), or weRACK (0.5 lmol/L). We also assessed the effect of the PKCe inhibitor peptide, eV1-2 (0.5 lmol/L), on the propofol-and AITC-induced phosphorylation of S729. PKCepS 729 levels were normalized to total PKCe protein levels detected in the lysate. In TRPV1 transfectedF-11 cells, neither AITC (100 lmol/L) nor propofol (10 lmol/L) increased PKCepS 729 levels as compared to untreated control (Fig. 3A) . However, treatment with the PKCe activator peptide, weRACK (0.5 lmol/ L), increased PKCepS 729 levels compared to control. In TRPV1-TRPA1 cotransfected F-11 cells, AITC, propofol, and weRACK all increased PKCepS 729 levels compared to control (Fig. 3C) . Moreover, the AITC-and propofolinduced increases in PKCepS 729 levels were prevented by pretreatment with the PKCe inhibitory peptide, eV1-2 in TRPV1-TRPA1 cotransfected F-11 cells (Fig. 3C) . In addition, following treatment with propofol (10 lmol/L) or AITC (100 lmol/L) in either cell type, the amount of immunodetectable PKCe in the membrane fraction was unchanged as compared to untreated control ( Fig. 3A and  C) . The Intralipid (amount equivalent to 10 lmol/L propofol) increased PKCepS 729 levels to 127 AE 8% of control similar to our previous findings (Wickley et al. 2010) . Summarized data for Figure 3A and C are depicted in Figure 3B and D, respectively.
Effect of propofol and AITC on TRPV1 phosphorylation at S800 in cultured F-11 cells expressing TRPV1 only or both TRPA1 and TRPV1
To determine if the presence of TRPA1 receptors is required for propofol or AITC to phosphorylate TRPV1 at S800, immunoblot analysis of TRPV1pS 800 was performed. TRPV1pS 800 levels were normalized to total TRPV1 protein detected in the lysate. In TRPV1 transfected F-11 cells, neither AITC (100 lmol/L) nor propofol (10 lmol/L) increased TRPV1pS 800 levels as compared to untreated control (Fig. 4A) . However, treatment with the PKCe activator peptide, weRACK (0.5 lmol/L), increased TRPV1pS 800 levels compared to control. In TRPV1-TRPA1 cotrasfected F-11 cells, AITC, propofol, and weRACK all increased TRPV1pS 800 levels compared to control (Fig. 4B) . Moreover, the AITCand propofol-induced increases in TRPV1pS 800 levels were prevented by pretreatment with the PKCe inhibitory peptide, eV1-2. In addition, following treatment Figure 3A and B, respectively, except in -11 cells transfected with both TRPV1 and transient receptor potential ankyrin receptor subtype-1 (TRPA1) channels. Data are expressed as a percent of the untreated control mean value AE SEM. *P < 0.05 compared to control. #P < 0.05 compared to AITC alone. †P < 0.05 compared to propofol alone. n = six different F-11 cell lysates.
with propofol (10 lmol/L) or AITC (100 lmol/L) in either cell type, the amount of immunodetectable TRPV1 in the cell lysate was unchanged as compared to untreated control ( Fig. 4A and C) . The Intralipid vehicle had no detectable effect on TRPV1pS 800 levels (103 AE 5% of control). Summarized data for Figure 4A and C are depicted in Figure 4B and D, respectively.
Effect of NOS inhibition on propofol-and AITC-induced restoration of TRPV1 sensitivity
In F-11 cells transfected with both TRPV1 and TRPA1, inhibition of NOS with L-NG-nitroarginine methyl ester (L-NAME; 100 lmol/L) prevented the propofol-induced restoration of TRPV1 sensitivity by more than 90% (Fig. 5B) . Moreover, the NO donor SNAP (100 lmol/L) mimicked the effects of propofol on restoration of TRPV1 sensitivity (Fig. 5C ) and the restoring effect of SNAP was inhibited by the PKCe inhibitor peptide (0.5 lmol/L), eV1-2 (Fig. 5D) . Similarly, the PKCe activator peptide weRACK (0.5 lmol/L) restored TRPV1 sensitivity in the presence of NOS inhibition with L-NAME (Fig. 5E) . Pretreatment with L-NAME alone did not restore sensitivity of TRPV1 to capsaicin (102 AE 9% of control). Summarized data for Figure 5A -E are depicted in Figure 5F . Effect of NOS inhibition on propofol-and AITC-induced PKCe phosphorylation at S729 in cultured F-11 cells expressing both TRPA1 and TRPV1
In F-11 cells transfected with TRPA1 and TRPV1, pretreatment with the NO donor, SNAP, increased immunodetectable phosphorylation of PKCepS 729 (Fig. 6A) . Moreover, inhibition of NOS with L-NAME prevented the propofol-and AITC-induced increase in immunodetectable PKCepS 729 . Incubation with L-NAME alone had no significant effect on basal levels of PKCepS 729 (98 AE 8% of control). Summarized data for Figure 6A are depicted in Figure 6B .
Effect of propofol and AITC on phosphorylation of NOS at Ser1417 and on NO production in cultured F-11 cells expressing both TRPA1 and TRPV1 No significant change in the expression level of nNOS was observed in nontransfected, TRPV1-trasfected, TRPA1-transfected, and TRPV1-TRPA1 cotransfected F-11 cells (Fig. 7A) . However, TRPV1-TRPA1 cotransfected F-11 cells pretreated with propofol (10 lmol/L) and AITC (100 lmol/L) demonstrated increased phosphorylation of nNOS at Ser 1417 compared to the nontreated cells lysate, that was significantly attenuated by the TRPA1 antagonist, HC-030031 (0.5 lmol/L; Fig. 7B ). Summarized data for Figure 7B are depicted in Figure 7C . AITC (100 lmol/L) -and propofol (10 lmol/L) -induced NO production was also detected and visualized in TRPV1-TRPA1 cotransfected F-11 cells, that was mimicked by SNAP (100 lmol/L). Moreover, propofol-induced NO production was attenuated in presence of HC-030031 (0.5 lmol/L). Changes in intracellular NO production were compared to cells pretreated with L-Arginine, an NO inducer (100 lmol/L), and c-PTIO, an NO scavenger (10 lmol/L) (Fig. 7) . Figure 4A and B, respectively, except in F-11 cells transfected with both TRPV1 channels and transient receptor potential ankyrin receptor subtype-1 (TRPA1) channels. Data are expressed as a percent of the untreated control mean value AE SEM. *P < 0.05 compared to control. #P < 0.05 compared to AITC alone. †P < 0.05 compared to Prop alone. n = six different F-11 cell lysates.
Discussion
This is the first study to delineate the role of PKCe in TRPA1-dependent restoration of TRPV1 sensitivity as well as to determine the mechanism by which TRPA1 activates PKCe. We previously demonstrated that propofol restores TRPV1 sensitivity via a PKCe-dependent phosphorylation of the channel (Wickley et al. 2010) and is dependent on the presence of functional TRPA1 receptors . However, the extent to which propofol activates these two pathways independently and in parallel or whether they are directly linked to one another via an unknown signaling pathway has not been established. Our key findings are that the AITC and propofol-induced restoration of TRPV1 sensitivity are mediated by a TRPA1-dependent activation of PKCe Moreover, TRPA1-induced activation of PKCe is mediated via a NOS-dependent pathway.
Our first objective was to determine the whether activation of PKCe is directly linked to TRPA1-dependent res-
(E) (F) Figure 5 . (A) Representative trace depicting the effect of propofol (Pro, 10 lmol/L) alone, L-NG-nitroarginine methyl ester (L-NAME; 100 lmol/L) plus propofol, S-nitroso-N-acetylpenicillamine (SNAP; 100 lmol/L) alone, SNAP plus protein kinase C epsilon (PKCe) inhibitor peptide eV1-2 (0.5 lmol/L), L-NAME plus the PKCe activator peptide ΨeRACK (0.5 lmol/L) after capsaicin-induced (100 nmol/L) desensitization on restoration of TRPV1 sensitivity to capsaicin (Cap) in mouse DRG neurons that contain functional TRPA1 and TRPV1 receptors are depicted in Figure 5A , B, C and D and E, respectively. The NOS inhibitor L-NAME was added alone for 5 min following desensitization and then propofol or the PKCe activator peptide ΨeRACK were brought on board in combination with L-NAME for an additional 5 min. Similarly, the eV1-2 inhibitor peptide was added alone for 5 min following desensitization and then SNAP was brought on board in combination with the eV1-2 inhibitor peptide for an additional 5 min. Summarized data for Figure 5A -E are depicted in Figure 5F . Data are expressed as a percent of the response to the final application of capsaicin in the untreated control (% of control mean value AE SEM). *P < 0.05 compared to final capsaicin in the untreated control. #P < 0.05 compared to Pro plus capsaicin. †P < 0.05 compared to SNAP plus capsaicin. n = F-11 cells from seven separate cover slips. toration of TRPV1 sensitivity. Our current results substantiate our previous findings that inhibition of PKCe prevents the propofol-induced restoration of TRPV1 sensitivity (Wickley et al. 2010 ) and our current novel findings indicate that the PKCe inhibition also prevents the AITC-induced restoration of TRPV1 sensitivity to agonist stimulation. These data are also consistent with previous findings demonstrating increased sensitivity of desensitized TRPV1 by phorbol esters occurs through PKCemediated phosphorylation of TRPV1 (Mandadi et al. 2006) .
|
Although our results indicate that PKCe is required for TRPA1 activation to restore TRPV1 sensitivity, indicating a TRPA1-dependent activation of PKCe, these results do not conclusively rule out the possibility that PKCe may activate TRPA1 and subsequently restore TRPV1 sensitivity. Therefore, we assessed the effect of the PKCe-specific activator peptide, weRACK, on restoration of TRPV1 sensitivity in F-11 cells expressing only TRPV1. Our findings indicate that direct activation of PKCe does not require the presence of TRPA1 receptors in order to restore TRPV1 sensitivity, and that TRPA1 stimulation is upstream of PKCe activation. Our current findings are similar to a previous study indicating that PKCe acts downstream of bradykinin and is principally responsible for sensitization of the heat response in nociceptors by bradykinin (Cesare et al. 1999) .
As part of the activation process, PKCe is autophosphorylated at S729 rendering it catalytically competent. Our results indicate that in cells containing TRPV1 and TRPA1, propofol and AITC phosphorylate PKCe at S729. This effect was markedly attenuated in F-11 cells containing only TRPV1 indicating that propofol primarily activates PKCe via a TRPA1-dependent pathway. It should be noted that in addition to the important role of PKCe in TRPV1 regulation, there may also be a direct molecular interaction between TRPA1 and TRPV1 that operates in parallel Salas et al. 2009; Staruschenko et al. 2010; Akopian 2011) .
The PKCe-dependent phosphorylation of TRPV1 at S800 has been shown to increase the sensitivity of TRPV1 to agonist stimulation (Zhou et al. 2001; Mandadi et al. 2006; Srinivasan et al. 2008 ). In the current study, we now demonstrate that TRPA1 is required for propofol or AITC to phosphorylate TRPV1 at S800 indicating a TRPA1-dependent signaling cascade leading to activation of PKCe and subsequent phosphorylation of TRPV1 at S800. We previously demonstrated that the propofol increased TRPV1pS 800 and that this increase was not observed in sensory neurons derived from PKCe À/À mice (Wickley et al. 2010) .
Previous studies in other cell types have indicated that NO donors are capable of activating specific PKC isoforms (Burgstahler and Nathanson 1995; Liang and Knox 1999; Harada et al. 2004; Lee et al. 2006) including PKCe (Nishio and Watanabe 1997; Ping et al. 1999; Bolli 2001; Balafanova et al. 2002) . In our study, NOS inhibition prevented the agonist-induced restoration of TRPV1 sensitivity. Moreover, the NO donor SNAP restored TRPV1 sensitivity, an effect that was abolished by PKCe inhibition and NOS inhibition failed to prevent restoration of TRPV1 sensitivity by the PKCe activator peptide. These data suggest that NO is a mediator of the TRPA1-dependent restoration of TRPV1 sensitivity and are consistent with a TRPA1-dependent induction of hyperthermia in rats which was dependent on NO production suggesting TRPA1 stimulates NOS activation (Ding et al. 2008) .
Some studies have demonstrated that NO donors can directly activate TRP channels causing increases in intracellular Ca 2+ (Yoshida et al. 2006; Miyamoto et al. 2009 ). In our study, we saw no increase in intracellular Ca 2+ upon application of SNAP in cells transfected with both channels. This may be due to the significantly lower concentration of SNAP (100 lmol/L) used in our study compared to others using concentrations between 1 and 5 mmol/L (Miyamoto et al. 2009 ).
In order to biochemically determine the extent to which TRPA1 activation is linked to NO production and activation of PKCe, we utilized F-11 cells transfected with both channels. In these studies, NOS inhibition with L-NAME prevented the agonist-induced increase in immunodetectable PKCcpS 729 . Moreover, SNAP stimulated an increase in immunodetectable PKCepS 729 . These data are consistent with the Ca 2+ imaging data indicating a TRPA1-dependent activation of NOS leading to NO-dependent phosphorylation of PKCe and restoration of TRPV1 sensitivity. The precise mechanism by which NO causes PKCe activation is not known but several possibilities exist. NO reacts with superoxide anions to form peroxynitrite that can activate PKC (Reiter et al. 2000; Chakraborti et al. 2005; Li et al. 2011) . Alternatively, the NO donor effect enhances PKC interaction with its specific anchor protein RACK2 via nitration of tyrosine residues of PKC, resulting in its activation (Balafanova et al. 2002) . This study also investigated the role of agonist-induced TRPA1 activation in activating nNOS and regulation of NO production in TRPV1 and TRPA1 coexpressing cells. Our data suggest that activation of TRPA1 leads to increased phosphorylation of nNOS at serine 1417 as well as NO production that is substantially attenuated in the presence of the TRPA1 antagonist, HC-030031. There were no significant changes in nNOS expression in any of the groups. These data further support the role of nNOS in TRPA1-mediated restoration of TRPV1 sensitivity and also confirms that nNOS is downstream of TRPA1.
Overall, our current findings are consistent with previous studies indicating cross talk between TRPV1 and TRPA1 receptors which regulate and modulate nociceptive ion channel function (Brand and Jacquot 2002; Akopian et al. 2007; Salas et al. 2009; Simons et al. 2010) . Moreover, our data indicating TRPA1-dependent activation of NOS, leading to PKCe activation and subsequent restoration of TRPV1 sensitivity provides new evidence needed to elucidate the mechanisms by which TRPA1 and TRPV1 regulate each other's function. A summary of the proposed cellular signaling pathway by which cross talk between TRPA1 and TRPV1 channels occurs is depicted in Figure 8 . The contribution of TRPV1 and TRPA1 to peripheral nociception supports the idea that one approach to control peripheral nociception is to better understand and manage cross regulation between TRPV1 and TRPA1 channels. A better understanding of these intricate mechanisms could prove vital in the search for therapeutic strategies to treat pathological conditions involving altered nociceptive processes. antibody was provided by M.Tominaga, Division of Cell Signaling, Okazaki Institute for Integrative Biosciences (National Institute for Physiological Sciences), Japan.
